Overview

A Study of YM060 in Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)

Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
This study will examine the efficacy, safety and tolerability of different oral dose of YM060, 5-HT3 receptor antagonist, in patients with d-IBS.
Phase:
Phase 2
Details
Lead Sponsor:
Astellas Pharma Inc
Collaborator:
Astellas Pharma Europe B.V.
Treatments:
Ramosetron